These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
586 related articles for article (PubMed ID: 30895453)
1. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution. Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453 [TBL] [Abstract][Full Text] [Related]
2. Functionalization of curcumin nanomedicines: a recent promising adaptation to maximize pharmacokinetic profile, specific cell internalization and anticancer efficacy against breast cancer. Zhang J; Sun J; Li C; Qiao H; Hussain Z J Nanobiotechnology; 2023 Mar; 21(1):106. PubMed ID: 36964547 [TBL] [Abstract][Full Text] [Related]
3. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer. Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374 [TBL] [Abstract][Full Text] [Related]
4. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy. Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400 [TBL] [Abstract][Full Text] [Related]
5. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy. Fang G; Zhang Q; Pang Y; Thu HE; Hussain Z J Control Release; 2019 Jun; 303():181-208. PubMed ID: 31015032 [TBL] [Abstract][Full Text] [Related]
6. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy. Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531 [TBL] [Abstract][Full Text] [Related]
7. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right. Sun D; Zhou S; Gao W ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091 [TBL] [Abstract][Full Text] [Related]
8. DePEGylation strategies to increase cancer nanomedicine efficacy. Kong L; Campbell F; Kros A Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090 [TBL] [Abstract][Full Text] [Related]
9. Copolymers of poly(lactic acid) and D-α-tocopheryl polyethylene glycol 1000 succinate-based nanomedicines: versatile multifunctional platforms for cancer diagnosis and therapy. Vijayakumar MR; Muthu MS; Singh S Expert Opin Drug Deliv; 2013 Apr; 10(4):529-43. PubMed ID: 23316695 [TBL] [Abstract][Full Text] [Related]
10. Vitamin E-based nanomedicines for anti-cancer drug delivery. Duhem N; Danhier F; Préat V J Control Release; 2014 May; 182():33-44. PubMed ID: 24631865 [TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment. Mao C; Li F; Zhao Y; Debinski W; Ming X Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297 [TBL] [Abstract][Full Text] [Related]
12. PEGylated PAMAM dendrimers: Enhancing efficacy and mitigating toxicity for effective anticancer drug and gene delivery. Luong D; Kesharwani P; Deshmukh R; Mohd Amin MCI; Gupta U; Greish K; Iyer AK Acta Biomater; 2016 Oct; 43():14-29. PubMed ID: 27422195 [TBL] [Abstract][Full Text] [Related]
13. Nanomedicine: clinical applications of polyethylene glycol conjugated proteins and drugs. Parveen S; Sahoo SK Clin Pharmacokinet; 2006; 45(10):965-88. PubMed ID: 16984211 [TBL] [Abstract][Full Text] [Related]
14. Rational Design of Cancer Nanomedicine for Simultaneous Stealth Surface and Enhanced Cellular Uptake. Jin Q; Deng Y; Chen X; Ji J ACS Nano; 2019 Feb; 13(2):954-977. PubMed ID: 30681834 [TBL] [Abstract][Full Text] [Related]
15. New developments and clinical transition of hyaluronic acid-based nanotherapeutics for treatment of cancer: reversing multidrug resistance, tumour-specific targetability and improved anticancer efficacy. Safdar MH; Hussain Z; Abourehab MAS; Hasan H; Afzal S; Thu HE Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1967-1980. PubMed ID: 29082766 [TBL] [Abstract][Full Text] [Related]
16. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Pérez-Herrero E; Fernández-Medarde A Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885 [TBL] [Abstract][Full Text] [Related]
17. Antibody-Incorporated Nanomedicines for Cancer Therapy. Wu SY; Wu FG; Chen X Adv Mater; 2022 Jun; 34(24):e2109210. PubMed ID: 35142395 [TBL] [Abstract][Full Text] [Related]
18. Combination antitumor therapy with targeted dual-nanomedicines. Dai W; Wang X; Song G; Liu T; He B; Zhang H; Wang X; Zhang Q Adv Drug Deliv Rev; 2017 Jun; 115():23-45. PubMed ID: 28285944 [TBL] [Abstract][Full Text] [Related]
19. Nanoparticles for Cancer Targeting: Current and Future Directions. Swain S; Sahu PK; Beg S; Babu SM Curr Drug Deliv; 2016; 13(8):1290-1302. PubMed ID: 27411485 [TBL] [Abstract][Full Text] [Related]